her2-positive gastrointestinal cancers: new evidence and practical guidance with targeted agents
Published 1 year ago • 709 plays • Length 1:18:52
Download video MP4
Download video MP3
Similar videos
-
1:01:07
protocols for her2-expressing gi cancers: refining btc and gea care with targeted agents
-
1:38:56
taking aim at gi cancers with personalized her2 and other molecularly targeted therapies
-
59:18
optimizing novel her2-targeted therapies and other agents in gastric cancer care
-
1:07:30
personalizing gastric cancer care with her2-targeted and other novel therapies
-
34:31
chair's take: her2-targeted and other agents for gastric cancer
-
1:30:06
moving toward expanded precision treatment of her2- or her3-driven breast, gi, lung & other cancers
-
33:06
maximizing the of potential current and emerging immunotherapies in advanced endometrial cancer
-
35:36
personalized treatment of advanced her2-negative gastric or gastroesophageal junction cancer
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
8:17
metastatic gastric cancer: indications and impact of targeting the her2 pathway?
-
1:34:58
see drs. elez & janjigian discuss her2-positive #gicancers @ #wcgic2022 https://bit.ly/barcelona-22
-
2:59
clinical implications of her2 in gi cancers
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
1:15:04
therapeutic advances and holistic care in gastric/gej cancers: a multidisciplinary approach
-
1:22:29
capitalizing on her2-targeted regimens to improve outcomes for gastric/gej cancers, crc, and btc
-
1:04:22
immunotherapy management of early and advanced gastric, esophageal, gej, and colorectal cancers
-
1:27:49
biomarker testing for new therapeutic options targeting her2, her3, and trop2 in solid tumors
-
1:18:32
advanced gi cancers: identifying and targeting uncommon but actionable genomic alterations
Clip.africa.com - Privacy-policy